Quebec Makes the Move to Reimburse Large B-Cell Lymphoma Treatment

MONTREAL, Aug. 17, 2023 /CNW/ – Incyte Biosciences Canada is pleased to announce that Quebec has made Minjuvi® (tafasitamab) in combination with lenalidomide accessible with reimbursement under the Régie de l’assurance maladie du Québec (RAMQ) for eligible patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This first listing follows a positive clinical recommendation by the health technology assessment agency Institut national d’excellence en santé et en services sociaux (INESSS)i in December 2022.

Read more at: